PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that Sairiyo Therapeutics Inc. ("Sairiyo"), a company 49% owned by PharmaTher and 51% owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF), is pursuing its strategic plans to focus on the clinical development of its patented enteric-coated oral Cepharanthine ("PD-001") as a potential therapeutic candidate...
Free plan · Plus CA$29 or Pro CA$99/month


